APA (7th ed.) Citation

Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J., Danese, S., . . . Song, A. (2022). Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet, 339(10340), 2031. https://doi.org/10.1016/S0140-6736(22)00466-4

Chicago Style (17th ed.) Citation

Ferrante, Marc, et al. "Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: Results from the Multicentre, Randomised, Double-blind, Placebo-controlled, Withdrawal Phase 3 FORTIFY Maintenance Trial." Lancet 339, no. 10340 (2022): 2031. https://doi.org/10.1016/S0140-6736(22)00466-4.

MLA (9th ed.) Citation

Ferrante, Marc, et al. "Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: Results from the Multicentre, Randomised, Double-blind, Placebo-controlled, Withdrawal Phase 3 FORTIFY Maintenance Trial." Lancet, vol. 339, no. 10340, 2022, p. 2031, https://doi.org/10.1016/S0140-6736(22)00466-4.